Titlebook: Diagnosis and Management of Testicular Cancer; The European Point o Susanne Krege Book 2015 Springer International Publishing Switzerland 2

江湖骗子

agitate

指数

圆桶

https://doi.org/10.1007/978-1-4842-9830-5ying from recurrent TC or a second cancer, TCS have a 6 % increased risk of mortality from non-cancer causes, including infections, cardiovascular disease (CVD), and respiratory disease after cisplatin-based chemotherapy compared with the general population [2].

讨人喜欢

Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cel9, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Kreg

甜食

Cabinet

Is There Still an Indication for Primary RPLND in Clinical Stage I Non-seminoma? A significant proportion (about two thirds) of patients with ascertained small nodal metastases at RPLND, are cured by surgery with no need of further therapy..The introduction of effective cisplatin-based chemotherapy has progressively reduced the role of primary RPLND in early stages NSGCT. This

Alopecia-Areata

傻瓜

Poor-Prognosis Germ Cell TumoursCT, extra-pulmonary visceral metastases or very high serum tumour marker levels (hCG > 50,000 UI/L, AFP > 10,000 ng/mL and/or LDH > 10 times the upper limit value). This subgroup of 10% patients is responsible for most of the deaths from GCT. Their progression-free survival rate is 41 % with only ha

VEN